Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 8-K (Current Report)
Date of Report: January 23, 2025 (Event Date); January 28, 2025 (Signature Date)
Reporting Period: The filing addresses events occurring in late 2024 and January 2025, specifically the termination of a financing agreement and recent capital raises.
Key Financial Metrics and Capital Activity
The filing does not provide audited revenue, profit, or cash flow statements. However, it details significant capital raising activities:
- Q4 2024 Capital Raises: $9.5 million in gross proceeds from two public offerings, $2.0 million from warrant exercises, and $3.1 million from the At-The-Market (ATM) program.
- January 2025 Capital Raise: An additional $4.25 million in gross proceeds from a subsequent public offering.
- Standby Equity Purchase Agreement (SEPA): The $25.0 million facility with YA II PN, LTD. (Yorkville) was terminated. No shares were issued, no borrowings were outstanding, and no fees are due upon termination.
- Liquidity Status: Management states these raises have strengthened the cash position and positioned the company to meet capital requirements without the SEPA.
Material Changes Versus Prior Period
The primary material change is the termination of the Standby Equity Purchase Agreement (SEPA) dated December 10, 2023. Unlike the prior period where this facility was active (though unexercised), it is now terminated as of January 23, 2025. This change is attributed to the successful execution of alternative capital raising strategies (public offerings and ATM program) that rendered the SEPA unnecessary.
Guidance, Outlook, and Risks
Management Commentary: Management believes the recent capital raises have bolstered the cash balance sufficiently to fund operations without reliance on the terminated SEPA framework. The ATM program remains available.
Outlook and Estimates: The financial data presented is preliminary and unaudited. The company's closing procedures for the fourth quarter and fiscal year ended December 31, 2024, are not yet complete. Actual results may differ materially from these estimates.
Risks and Contingencies:
- Preliminary Data Risk: The financial figures are estimates subject to internal review and final adjustments.
- Forward-Looking Statements: Future performance is subject to known and unknown risks, including competitive pressures and the rapidly changing biotech environment.
- Regulatory Status: The company is an emerging growth company.
Investor Verification Checklist
- Verify the final audited cash balance and burn rate in the upcoming 10-K filing for the year ended December 31, 2024.
- Confirm the exact net proceeds (after expenses) from the Q4 2024 and January 2025 public offerings.
- Review the status and remaining capacity of the At-The-Market (ATM) program.
- Monitor for any new financing agreements or material definitive agreements filed in subsequent 8-K reports.